James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

3 ETFs to Play Rising Bond Yields

Rising bond yields got you down? Try one of these exchange-traded funds that will survive, if not thrive, in a rising-rate environment.

Gold’s Collapse Is Not Done

The yellow metal's been eviscerated lately, but the charts suggest the pain isn't over for gold fans. Look for a continued plunge toward $1,200.

Arena, Vivus Look Good (And It Has Nothing to Do With the AMA)

The AMA has ruled to classify obesity more intensely -- as a "disease." But are ARNA and VVUS investors justified in being excited?

Brokerage Firm Stocks: Just Getting Started

Brokerage firms have been demolishing market returns this year, and if investors stay bullish about the economy, there's still plenty more money to be made.

So Your DNA Can’t Be Patented … Now What?

The Supreme Court recently ruled that identifying genes is not patentable ... which is both good and bad news for DNA-mapping companies.